AG
BCAX

Ascent Group’s Bicara Therapeutics BCAX Stock Holding History

Ascent Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Buy
14,176
+24
+0.2% +$536 0.01% 576
2026
Q1 		$281K Buy
14,152
+1
+0% +$17 0.01% 640
2025
Q4 		$238K Buy
14,151
+221
+2% +$3.77K 0.01% 674
2025
Q3 		$220K Buy
+13,930
New +$156K 0.01% 684

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ascent Group's BCAX Position: Q2 2026 in Review

Ascent Group increased its Bicara Therapeutics (BCAX) stake by 0.17% in Q2 2026, buying an estimated $536 and bringing the position to 14,176 shares worth $421K. The position accounts for 0.01% of the portfolio, ranked #576.

Ascent Group first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Ascent Group held 14,176 shares of Bicara Therapeutics worth $421K as of Q2 2026.
  • Ascent Group bought 24 Bicara Therapeutics shares in Q2 2026, an estimated $536.
  • Bicara Therapeutics made up 0.01% of Ascent Group's portfolio in Q2 2026, its #576 holding.
  • Ascent Group first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.